Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
← Back to archive
2022 Michigan Disadvantage

DA - Politics BBB 2 - Michigan 7 2022 FMPS

DA - Politics BBB 2 - Michigan 7 2022 FMPS.docx

Download Word file
Indexed text preview
Negative
Uniqueness---Will Pass
BBB can pass by the end of July. Dems are hopeful and are moving quickly because of looming midterms, but PC is key to resolve remaining issues.
Zhou 7/6 (Li Zhou is a policy reporter at Vox and formerly worked on tech policy at politico and former fellow at The Atlantic. “Democrats’ latest attempt at resurrecting Build Back Better, explained,” Vox. July 6, 2022. Accessed July 10, 2022. https://www.vox.com/2022/7/6/23197398/build-back-better-prescription-drug-prices, AK)
This month, Democrats are, once again, trying to resurrect parts of the Build Back Better Act after the broader package imploded last year.
To do so, the party is focusing on provisions aimed at lowering prescription drug costs, something that has the full support of all 50 Senate Democrats. Negotiations on more contentious climate and tax policies, meanwhile, are ongoing.
On Wednesday, following an agreement between Senate Majority Leader Chuck Schumer (D-NY) and Sen. Joe Manchin (D-WV) — one of the key holdouts on the original BBB package — lawmakers officially submitted the prescription drugs plan to the Senate parliamentarian for review. The parliamentarian, a nonpartisan procedural expert, will determine if the proposal can qualify for the budget reconciliation process, which enables policies that affect the budget to pass with 51 votes in the Senate, rather than the 60 needed if a bill is filibustered under normal rules.
Schumer and Manchin are still in talks about additional climate and tax provisions that could be included in the legislation, but it’s uncertain whether those will make it into a final bill. It also isn’t clear where Sen. Kyrsten Sinema (D-AZ), who once opposed certain corporate tax hikes in the original BBB bill, stands on those two issues. (Previously, Sinema appeared satisfied with some of the updated BBB tax policies that had been negotiated last year.)
Although there are still outstanding subjects to work on, Democrats are hopeful that movement on prescription drugs will both allow the party to achieve a longtime goal, and to signal to midterms voters that Democratic lawmakers can make progress on something.
The prescription drugs proposal — though much narrower than its previous iteration — is significant: It would enable Medicare to negotiate prices on a select group of drugs beginning in 2023 and cap Medicare patients’ out-of-pocket drug costs at $2,000 a year. But if it is all Democrats are able to pass, the party will have fallen far short of what it had initially strived to achieve with the Build Back Better Act, which included substantial funding for green energy tax credits and social programs as well.
What Democrats have agreed on so far
Thus far, Democrats are aligned on their prescription drugs plan and not much else. The plan aims to make some drugs more affordable, though it drops some original BBB proposals, like a $35 monthly cap on insulin costs.
As Manchin had previously said, his goal is for the legislation to be a deficit-reduction bill, with about 50 percent of the revenue it’s bringing in going to paying down the deficit, and the other half going to cover new spending. A major chunk of new revenue is likely to come from the prescription drug policies, since they could include billions in savings for Medicare. Here are the prescription drug provisions that Democrats agree on so far:
Allowing Medicare to negotiate drug prices: Medicare has historically been barred from negotiating on most prescription drug prices, meaning it pays drug prices set by the market. This bill would change that. In doing so, it could mean drastic price reductions on specific drugs for people covered by Medicare, since the government has huge buying and negotiating power.
The savings would not apply to people covered by private insurance, however, Reuters reports. The legislation guarantees that Medicare can begin negotiations in 2023, starting with 10 drugs, which will be chosen by the Department of Health and Human Services.
Capping out-of-pocket drug costs for Medicare recipients: The legislation would cap annual out-of-pocket drug costs for Medicare recipients at $2,000. After that, Medicare would pay for additional expenses. It would be a major change since there is currently no cap, meaning people can spend thousands more for a single drug.
Requiring rebates for price hikes: If pharmaceutical companies raise the costs of a drug at a rate faster than the rate of inflation, they would be forced to refund the difference to people paying for the drug.
Expanding prescription drug subsidies for low-income seniors: Currently, seniors who are at or below 150 percent of the federal poverty line are able to receive a partial subsidy for their prescription drugs. The legislation would enable them to receive a larger subsidy for these expenses.
Making vaccines free for seniors: The legislation would make all vaccines free for seniors, a notable change in coverage. Currently, Medicare covers some vaccines, like the flu shot, but not all immunizations are included.
Democrats are trying to do what they can before the midterms
Although Democrats’ electoral chances in the Senate are looking better than they are in the House, it’s possible the party loses control of one or both chambers of Congress following the November midterms. With the elections fast approaching, Democrats are scrambling to capitalize on their existing majorities in case they are no longer able to pass legislation next year.
This reconciliation bill could be the party’s last major chance to approve new prescription drugs, climate, and tax policy — all of which would be far less likely to advance if Republicans retake just one chamber of Congress. If they are able to make quick progress in the coming weeks, it’s possible that Democrats could hold a vote on the reconciliation bill as soon as the end of July.
Republicans are aggressively pushing back on these efforts: Senate Minority Leader Mitch McConnell has threatened to pull support on a bipartisan bill aimed at investing in the US’s supply chain unless Democrats abandon reconciliation. Democrats have responded by claiming McConnell is trying to deter the reconciliation bill in order to protect pharmaceutical companies.
To successfully push through a reconciliation bill, however, Senate Democrats need all 50 members of their caucus on board with the legislation, as well as approval from the parliamentarian — who can advise against including provisions if they aren’t seen as sufficiently related to taxing and spending. House Democrats, many of whom have pushed for a more ambitious bill in the past, would need to vote in favor as well. Recent comments from House Speaker Nancy Pelosi suggest that some lawmakers would be open to a smaller bill if it meant getting part of the package done.
For now, the submission of the prescription drugs proposal indicates that Democrats are at least trying to pass a bill, even if there’s no guarantee that other, more expansive provisions will be included.
A slimmed-down bill passes. Manchin and Schumer are on board and are negotiating in good faith, progressives agree, and the bill solves climate.
Berman 7/8 (Russell Berman is a staff writer at The Atlantic. Since joining The Atlantic in 2014, Russell has written extensively about Congress, political reform, and policy experiments in states and cities. He previously covered the House of Representatives for The Hill newspaper and served as a Washington correspondent for the New York Sun. “Democrats Try to Build Back (A Bit) Better,” The Atlantic. July 8, 2022. Accessed July 9, 2022. https://www.theatlantic.com/politics/archive/2022/07/democrats-manchin-schumer-biden-deal-build-back-better-bill/661512/, AK)
President Joe Biden’s economic agenda might be back from the dead. If the original proposal was Build Back Better, this is more like Build Back a Bit.
Democrats this week took the first formal step toward reviving a stripped-down version of the nearly $2 trillion plan that Senator Joe Manchin killed late last year. Majority Leader Chuck Schumer asked the Senate parliamentarian to review a proposed agreement that aims to reduce the cost of prescription drugs by allowing Medicare to negotiate prices directly—a long-sought Democratic priority that Manchin supports. That is one major component of a deal Schumer and Manchin have been discussing that would include hundreds of billions of dollars to combat climate change along with deficit-slashing tax increases on the wealthy.
The deal could be ready for votes on the Senate floor by the end of this month, according to a Democrat familiar with the talks who described the development as “major progress” toward enacting a chunk of Biden’s program before the midterm elections. Caveats abound: Schumer and Manchin have yet to complete either the tax or the climate portions of the bill, and the West Virginia centrist has abandoned negotiations before. With no Republican support, Democrats need the parliamentarian to determine whether their proposal can qualify for the process known as budget reconciliation, which would circumvent an expected filibuster and allow a bill to pass with a simple majority vote. A second Democratic aide, who like the first spoke anonymously to describe the delicate discussions, told me that a final deal would “probably take several weeks” and characterized the hopes for a vote before Congress breaks for its August recess as “ambitious.”
Yet the fact that the Schumer-Manchin talks have advanced even this far counts as a welcome surprise for Democrats, especially considering how acrimoniously the original Build Back Better negotiations collapsed in December. Manchin walked away after accusing the White House of putting his family at risk by singling him out in an otherwise anodyne statement describing the status of the discussions. In announcing his decision on Fox News, he further complained that the Democrats’ proposal was full of budget gimmicks and could worsen inflation. Because Manchin represented the crucial 50th vote in the evenly divided Senate, his departure ended Biden’s hopes of delivering on a progressive agenda that initially included a federal paid-leave program, universal pre-kindergarten, free community college, and an extension of the president’s expanded child tax credit.
The negotiations remained dormant through the winter. “There is no Build Back Better bill,” Manchin told reporters in February. “It’s dead.” But he and Schumer quietly began talking again in the spring, keeping their negotiations secret both to avoid the daily pestering of the Capitol Hill press corps and to prevent Democrats from getting their hopes up. Gone are many of the items on Biden’s original wish list, as is the original $3.5 trillion price tag. The total revenue Schumer and Manchin now hope to generate through tax increases and drug-pricing reform is likely to be in the area of $1 trillion, with about $500 billion in new spending on climate and energy policies.
Any deal that Schumer and Manchin strike will probably win applause from the bulk of the Democratic Party, including progressives. A $1 trillion bill might seem paltry next to the dream of $3.5 trillion, but it’s a lot better than the nothing that most Democrats have expected to get for the past six months. “The contours are fine,” Adam Green, a co-founder of the Progressive Change Campaign Committee, told me about the potential deal. He said the climate piece was “by far” the most important aspect of the package for progressives, especially in light of last month’s Supreme Court decision limiting the EPA’s ability to fight climate change. “We can’t reverse the Trump tax cuts if the planet disintegrates. The other two [proposals] are political winners,” Green said of the drug-pricing reforms and tax increases. “Climate change is just existential for the planet, and this might be our last chance.”
Another sign that the negotiations are serious is that Senate Minority Leader Mitch McConnell tried to torpedo them last week by threatening to pull GOP support from a bipartisan high-tech manufacturing bill if the Democrats moved forward with the one-party reconciliation progress. Schumer’s move today suggests that at least for now, McConnell’s warning hasn’t scared off Manchin.
BBB is top of Democrat’s agenda and can pass by August, but continued negotiations are key to iron out the details.
Everett and Levine 7/7 (John Burgess Everett is the congressional bureau chief for POLITICO, specializing in the Senate since 2013. He’s a native Mainer, a University of Maryland graduate and one of those people who goes by his middle name. Before covering the Senate, Burgess covered transportation policy for POLITICO and served on the production team. He’s also an alum of the Gazette in suburban Maryland and the Portland Press Herald in Maine. Marianne LeVine is a reporter for POLITICO, where she covers the Senate. She previously covered lobbying and co- authored POLITICO Influence. Prior to her stint on the lobbying beat, Marianne covered labor policy for POLITICO Pro, writing about regulations related to overtime pay, retirement advice and occupational health and safety. Her reporting in 2016 about domestic abuse allegations against President Donald Trump's first nominee for labor secretary, Andrew Puzder, was a key part of the debate surrounding his nomination, which he ultimately withdrew. Prior to working at POLITICO, Marianne was an intern in the Los Angeles Times' Washington, D.C. bureau. She graduated from Stanford undergrad in 2013, with degrees in International Relations and French and completed Stanford's Graduate Program in Journalism in 2014. Zack Colman contributed to the report. “Dems' climate and tax agenda to consume Congress in July,” Politico. July 7, 2022. Accessed July 10, 2022. https://www.politico.com/news/2022/07/07/dems-climate-tax-agenda-july-00044482, AK)
Democrats are taking tangible steps towards a deal on their party’s signature spending bill, expecting the proposal to dominate the rest of July and hoping it could reshape their political fortunes after six months of stasis.
Talks between Majority Leader Chuck Schumer and Sen. Joe Manchin (D-W.Va.) are beginning to yield concrete results on a potential climate, tax and prescription drugs package. Schumer told Senate Democrats recently that if he can reach a deal with Manchin, the bill could be on the floor as soon as this month, according to a person familiar with the negotiations.
Negotiators are still ironing out key details, but Democrats are signaling that as soon as next week they will begin arguing their case to the Senate rules chief on why the package should pass with a simple majority in the chamber. No one is getting their hopes too high in a party still reeling from Manchin’s rejection of Build Back Better, Democrats’ previous version of the legislation.
Democrats interviewed for this story ranged from near-certain there will be a deal to fretful that anything will ever materialize.
“I am generally optimistic. I’ll believe it when there’s a deal,” said Sen. Chris Coons (D-Del.) on Thursday. “I believe there is positive momentum, I believe there have been constructive conversations. But the specifics, the details, I think it’s best to let that work itself out.”
Democrats solved the easiest piece of their puzzle this week: finalizing a prescription drug pricing reform deal from last year, which both lowers prices and is expected to raise at least $250 billion in revenues. Democrats submitted that piece to the Senate parliamentarian for review, trying to ensure it doesn’t run afoul of the strict chamber rules that govern whether legislation can pass with a simple majority, known as budget reconciliation.
And they plan to soon submit an additional piece on a deal that extends Medicare solvency. Both those pieces are expected to have the support of all 50 Senate Democrats.
Shaving down the $555 billion energy package from the abandoned Build Back Better bill is proving tougher; Manchin is looking at energy spending of around $300 billion and ultimately new subsidies for electric vehicles could be cut, according to a second person familiar with the negotiations. Democrats are also trying to prevent health care premiums from skyrocketing this fall, and they need to detail tax increases and enforcement that would both pay for the bill and reduce the deficit, priorities of Manchin’s.
Roughly speaking, Manchin and Schumer are working toward legislation that provides $1 trillion in new revenues, half of which would go toward deficit reduction and half of which would go toward energy and health spending. Such a deal is hypothetical at the moment: The tax and energy pieces remain in major flux.
“Senator Manchin has repeatedly expressed his concerns about rising inflation, a pending recession and the state of American energy security. He continues to work in good faith to see if there is a pathway forward to shore up domestic energy production and reduce emissions, lower health care costs for seniors and working families, and ensure everyone is paying their fair share of taxes,” said Sam Runyon, a spokeswoman for Manchin.
Schumer declined to comment on negotiations but said recently that he and Manchin are “continuing to have very good and productive discussions.” Both men are keeping their talks close to the vest given their up-and-down history: Manchin and Schumer entered into a secret reconciliation agreement last July, Manchin rejected President Joe Biden’s Build Back Better bill in December and Manchin blanched at both Biden and Schumer’s attempts to weaken the legislative filibuster this year.
Internal---Midterms
BBB is a massive victory for Democrats in midterms.
Berman 7/8 (Russell Berman is a staff writer at The Atlantic. Since joining The Atlantic in 2014, Russell has written extensively about Congress, political reform, and policy experiments in states and cities. He previously covered the House of Representatives for The Hill newspaper and served as a Washington correspondent for the New York Sun. “Democrats Try to Build Back (A Bit) Better,” The Atlantic. July 8, 2022. Accessed July 9, 2022. https://www.theatlantic.com/politics/archive/2022/07/democrats-manchin-schumer-biden-deal-build-back-better-bill/661512/, AK)
As I wrote last year, the political advantage of Biden’s economic agenda was always its size and ambition, because that meant with slim margins in Congress, it could withstand plenty of cuts and still represent a significant legislative accomplishment. That remains true today, perhaps even more so. An agreement on drug pricing, climate spending, and tax increases, combined with Biden’s $1.9 trillion American Rescue Plan, the $1 trillion infrastructure law, and the recent bipartisan gun-safety compromise, would make the president’s legislative record look a lot more robust.
Politically, a scaled-down bill that passes close to the midterm elections, when it will be fresh in voters’ minds, might be just as beneficial to Democrats as a larger bill enacted months earlier. Each of the major components has clear constituencies. Lowering the cost of prescription drugs is a particular hit with seniors, a key voting bloc, and Democrats also plan to sell the change as a way to offset the impact of inflation. Combatting climate change is a priority of progressive and younger voters, whom Democrats need to turn out in November. And polls have long shown that tax increases on the wealthy are among the most broadly popular proposals in Biden’s plan.
Internal---Climate
BBB passes and is the last chance to meet climate goals. It’s valuable even if they win we can’t solve all of climate.
Peters 7/6 (Adele, A STAFF WRITER AT FAST COMPANY WHO FOCUSES ON SOLUTIONS TO SOME OF THE WORLD'S LARGEST PROBLEMS, FROM CLIMATE CHANGE TO HOMELESSNESS. PREVIOUSLY, SHE WORKED WITH GOOD, BIOLITE, AND THE SUSTAINABLE PRODUCTS AND SOLUTIONS P

Preview shortened. Download the file for the full document.